Codex DNA to Showcase Innovative SOLA Enzymatic DNA Synthesis Technology and Automated Benchtop BioXp System at SynBioBeta’s Built with Biology Global Conference
April 06 2022 - 8:03AM
Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated
benchtop synthetic biology systems, today announced its speaker
lineup for presentations at SynBioBeta’s Built with Biology Global
Conference, which is being held in Oakland, Calif., on April 12-14,
2022. Codex DNA will be showcasing its proprietary short oligo
ligation assembly (SOLA) enzymatic DNA synthesis (EDS) technology
and its BioXp™ products for end-to-end automated workflows at booth
#11.
Codex DNA’s unique SOLA approach addresses many of the
challenges facing existing EDS methods related to build length,
cost, fidelity, and scalability into synthetic biology workflows.
Unlike alternative technologies that employ terminal
deoxynucleotidyl transferase (TdT), which incorporates one DNA
letter at a time, the streamlined SOLA process generates
high-quality synthetic DNA from a universal, pre-manufactured
library of short DNA oligos. The short oligos provide the building
blocks needed to efficiently assemble complex synthetic genes and
mRNA templates using Codex DNA’s industry-standard Gibson Assembly®
method on the automated BioXp system. Together, the SOLA technology
and BioXp system have the potential to significantly reduce
timelines for constructing synthetic DNA, RNA, and proteins for
numerous downstream applications including vaccine development,
therapeutics development, diagnostics, precision medicine, and DNA
data storage.
FEATURED PODIUM
PRESENTATIONS:
- Democratizing Synthetic Biology through SOLA Enzymatic DNA
Synthesis and Workflow AutomationPresenters: Todd
Nelson, PhD, CEO, Codex DNA and Dan Gibson, PhD, CTO, Codex
DNADate/Time: Tuesday, April 12, 1:30-2:15 pm
PTLocation: Breakout Room 3
- Using Rapid Design-Build-Test Cycles to Transform Legacy Supply
Chains via BiomanufacturingPresenters: Ben
Chiarelli, CEO, Cellibre and Todd Nelson, PhD, CEO, Codex
DNADate/Time: Wednesday, April 13, 1:30-2:15 pm
PTLocation: Breakout Room 2
CODEX DNA TECHNOLOGY DEMONSTRATIONS (Booth
#11):
- DNA Libraries on the BioXp SystemPresenter:
Kurt Klimpel, PhD, Senior Director, Customer Solutions, Codex
DNADate/Time:
Tuesday, April 12,
8:30-9:00 am PTWednesday, April 13, 1:00-1:30 pm PTThursday, April
14, 8:30-9:00 am PTLocation: Codex DNA booth
#11
- Automated mRNA Synthesis on the BioXp
systemPresenter: Katie Lyons, Director, Field
Applications Science, Codex DNADate/Time:
Tuesday, April 12,
1:00-1:30 pm PTWednesday, April 13, 8:30-9:00 am PTThursday, April
14, 1:00-1:30 pm PTLocation: Codex DNA booth
#11
“Codex DNA is proud to present and participate at the preeminent
SynBioBeta Built with Biology Global Conference,” said Todd R.
Nelson, PhD, CEO of Codex DNA. “We are looking forward to sharing
the latest advances from our innovative SOLA EDS technology and
automated benchtop solutions that will ultimately enable customers
to create high-quality DNA, RNA, and proteins in their own
laboratories. Our sustainable, scalable, and cost-effective
approach has been designed to significantly accelerate development
timelines for the next wave of mRNA-based vaccines and other
diagnostics, therapeutics, and personalized
medicines.”About Codex DNACodex DNA is empowering
scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Codex DNA is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp™ system consolidates, automates
and optimizes the entire synthesis, cloning and amplification
workflow. As a result, it delivers virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Codex DNA is a public company
based in San Diego. For more information, visit codexdna.com.
Codex DNA, the Codex DNA logo, Gibson Assembly, and BioXp are
trademarks of Codex DNA Inc.
Forward-Looking StatementsThis press release
contains forward-looking statements. All statements other than
statements of historical facts contained herein are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
include statements regarding Codex DNA’s progress made on achieving
corporate goals and the future release of products and services.
Such statements are based on current assumptions that involve risks
and uncertainties that could cause actual outcomes and results to
differ materially. These risks and uncertainties, many of which are
beyond Codex DNA’s control, include risks described in Codex DNA’s
public filings, specifically the section entitled Risk Factors and
elsewhere in its annual Report on Form 10-K, which is anticipated
to be filed with the Securities and Exchange Commission on March
23, 2022. These forward-looking statements speak only as of the
date hereof and should not be unduly relied upon. Codex DNA
disclaims any obligation to update these forward-looking
statements.
Media Contact Richard D. LepkeDirector,
Investor Relationsir@codexdna.com
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jul 2023 to Jul 2024